Ad
related to: chemotherapy induced anemia treatment guidelines
Search results
Results from the WOW.Com Content Network
Desidustat is developed for the treatment of anemia as an oral tablet, where currently injections of erythropoietin and its analogues are drugs of choice. Desidustat is a HIF prolyl-hydroxylase inhibitor. In preclinical studies, effects of desidustat was assessed in normal and nephrectomized rats, and in chemotherapy-induced anemia.
Epoetin alfa is indicated for the treatment of anemia due to chronic kidney disease; zidovudine in people with human immunodeficiency virus; HIV infection; the effects of concomitant myelosuppressive chemotherapy; reduction of allogeneic red blood cell transfusions.
In June 2001, it had been approved by the European Medicines Agency for this indication as well as the treatment of anemia in cancer patients undergoing chemotherapy. [5] Dr. Reddy's Laboratories launched darbepoetin alfa in India under the brand name Cresp in August 2010. This is the world's first follow-on biologic of darbepoetin alfa.
The treatments for cytopenia vary depending on the type of cytopenia. The treatment for anemia is rest and a diet consisting of high iron foods. Medication can also be used such as: [citation needed] Epoetin alfa, a synthetic erythropoietin that stimulates stem cells to produce red blood cells.
Patients with iron deficiency anemia and an unsatisfactory history with oral iron have a real need for additional treatment options and the data from the studies presented at ASH suggest that ...
There are a number of strategies in the administration of chemotherapeutic drugs used today. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent.
ESAs are used in the treatment of anemia in chronic kidney disease, anemia in myelodysplasia, and in anemia from cancer chemotherapy. Risks of therapy include death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence. Risk increases when EPO treatment raises hemoglobin levels over 11 g/dL to 12 g/dL: this is to be avoided.
An appropriate course of treatment for drug-induced autoimmune hemolytic anemia hasn't yet been established. Once DIIHA has been recognized, the patient must stop whatever drug caused the anemia in order to provide proper treatment. Patients should be given blood transfusions as needed.
Ad
related to: chemotherapy induced anemia treatment guidelines